# Relay Therapeutics, Inc.: overview

RLAY · Nasdaq · CIK 1812364 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rlay.md) · [Financials](/companies/rlay/financials.md) · [Filings](/companies/rlay/filings.md) · [Insiders](/companies/rlay/insiders.md)

Latest reported revenue: [$350.0k](/filings/0001193125-26-338056.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-338056).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001193125-25-269601.md) | [0.0 d](/filings/0001193125-26-076739.md) | [7.7](/filings/0001193125-26-206454.md) | [0.7](/filings/0001193125-26-338056.md) | [0.0](/filings/0001193125-25-269601.md) | [7.0 d](/filings/0001193125-26-076739.md) | [3.0](/filings/0001193125-26-206454.md) | [0.4](/filings/0001193125-26-338056.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | [(1105.2%)](/filings/0001193125-26-206454.md) | [(11351.1%)](/filings/0001193125-26-338056.md) | not reported | [(866.1%) d](/filings/0001193125-26-076739.md) | [(2619.7%)](/filings/0001193125-26-206454.md) | [(25949.7%)](/filings/0001193125-26-338056.md) |
| Net margin | % | not reported | not reported | [(1003.6%)](/filings/0001193125-26-338056.md) | [(10395.1%)](/filings/0001193125-26-338056.md) | not reported | [(784.1%) d](/filings/0001193125-26-076739.md) | [(2443.0%)](/filings/0001193125-26-338056.md) | [(23916.3%)](/filings/0001193125-26-338056.md) |
| Diluted EPS | $ per share | [(0.63)](/filings/0001193125-25-269601.md) | not reported | [(0.46)](/filings/0001193125-26-206454.md) | [(0.41)](/filings/0001193125-26-338056.md) | [(0.43)](/filings/0001193125-25-269601.md) | not reported | [(0.41)](/filings/0001193125-26-206454.md) | [(0.41)](/filings/0001193125-26-338056.md) |
| Free cash flow | $m | [(75.3) d](/filings/0001193125-25-269601.md) | [(57.9) d](/filings/0001193125-26-076739.md) | [(73.6)](/filings/0001193125-26-206454.md) | [(55.3) d](/filings/0001193125-26-338056.md) | [(62.1) d](/filings/0001193125-25-269601.md) | [(44.9) d](/filings/0001193125-26-076739.md) | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3.0](/filings/0000950170-24-018797.md) | [1.4](/filings/0000950170-25-027756.md) | [25.5](/filings/0001193125-26-076739.md) | [10.0](/filings/0001193125-26-076739.md) | [15.4](/filings/0001193125-26-076739.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(12040.2%)](/filings/0000950170-24-018797.md) | [(21670.9%)](/filings/0000950170-25-027756.md) | [(1460.1%)](/filings/0001193125-26-076739.md) | [(3722.1%)](/filings/0001193125-26-076739.md) | [(1971.6%)](/filings/0001193125-26-076739.md) |
| Net margin | % | [(12012.9%)](/filings/0000950170-24-018797.md) | [(21036.1%)](/filings/0000950170-25-027756.md) | [(1338.7%)](/filings/0001193125-26-076739.md) | [(3374.7%)](/filings/0001193125-26-076739.md) | [(1800.6%)](/filings/0001193125-26-076739.md) |
| Diluted EPS | $ per share | [(3.82)](/filings/0000950170-24-018797.md) | [(2.59)](/filings/0000950170-25-027756.md) | [(2.79)](/filings/0001193125-26-076739.md) | [(2.36)](/filings/0001193125-26-076739.md) | [(1.61)](/filings/0001193125-26-076739.md) |
| Free cash flow | $m | [(77.9)](/filings/0000950170-24-018797.md) | [(239)](/filings/0000950170-25-027756.md) | [(304)](/filings/0001193125-26-076739.md) | [(251)](/filings/0001193125-26-076739.md) | [(236)](/filings/0001193125-26-076739.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rlay/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [SB INVESTMENT ADVISERS (UK) LTD](/funds/1731509.md) | 2026-06-30 | $522.1m | 27,904,963 |  | Unchanged |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $376.3m | 20,110,113 |  | Added +16,414,682 |
| [Casdin Capital, LLC](/funds/1534261.md) | 2026-06-30 | $300.0m | 16,035,240 |  | Added +1,616,666 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $286.0m | 15,288,202 |  | Added +2,312,903 |
| [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $263.9m | 14,106,187 |  | Added +4,355,046 |
| [Commodore Capital LP](/funds/1831942.md) | 2026-06-30 | $224.5m | 12,000,000 |  | Reduced −5,000,000 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $189.5m | 10,125,381 |  | Added +3,891,836 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $167.7m | 8,964,423 |  | Added +1,576,958 |
| [Nextech Invest Ltd.](/funds/1595430.md) | 2026-06-30 | $126.8m | 6,776,506 |  | Added +1,250,000 |
| [Bellevue Group AG](/funds/1674546.md) | 2026-06-30 | $115.7m | 6,185,970 |  | Reduced −1,609,272 |

## Recent filings

[All 550 filings](/companies/rlay/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 16:15 ET | [10-Q](/filings/0001193125-26-338056.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338056 |
| 2026-08-06 | 16:11 ET | [8-K](/filings/0001193125-26-338013.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-338013 |
| 2026-06-09 | 16:35 ET | [8-K](/filings/0001193125-26-263873.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-263873 |
| 2026-05-21 | 17:07 ET | [8-K](/filings/0001193125-26-234862.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-234862 |
| 2026-05-19 | 08:45 ET | [8-K](/filings/0001193125-26-229770.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-229770 |
| 2026-05-05 | 16:15 ET | [10-Q](/filings/0001193125-26-206454.md) | Quarterly report, period 2026-03-31 | 0001193125-26-206454 |
| 2026-05-05 | 16:10 ET | [8-K](/filings/0001193125-26-206398.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-206398 |
| 2026-04-28 | 16:05 ET | [DEF 14A](/filings/0001193125-26-186929.md) | Proxy statement, period 2026-06-09 | 0001193125-26-186929 |
| 2026-04-27 | 09:15 ET | [8-K](/filings/0001193125-26-179404.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-179404 |
| 2026-03-16 | 08:30 ET | [8-K](/filings/0001193125-26-107312.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-107312 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-076739.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/8ff7842a-5f44-4f81-b4d8-152c3890bb10)

## About the filer

- CIK: 1812364
- Tickers: RLAY
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:27 ET. No prices; not investment advice.